Russian Coronavirus Vaccine to Undergo Preclinical Tests on People

23 April 2020

GMP News

Russia’s Vector State Research Center of Virology and Biotechnology has formed a preliminary group of volunteers aged between 18 and 60 for preclinical trials of vaccine against the novel coronavirus, researcher Natalya Dumchenko has said.

Vector Director General Rinat Maksyutov said in early April that preclinical tests will begin in early May and last until June 22. The vaccine has already been tested on animals.

‘We have formed a preliminary group of volunteers, aged between 18 and 60, with the verified ‘healthy’ status. In other words, we have healthy volunteers without chronic conditions,” Dumchenko said in an interview to the information center that monitors the novel coronavirus situation.

She said that the majority of those volunteers are Vector employees, who are involved in developing the vaccine and checking its quality.

“In the run-up to the vaccination – no earlier than one week before it – an additional health screening will be held to confirm the ‘healthy’ status and the absence of antibodies to the virus,” Dumchenko added.

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more